New cocktail of cancer drugs shows promise in early lymphoma trial

NCT ID NCT05169515

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 11, 2026 · Updated 5 times

Summary

This early-stage trial is testing whether combining two existing immunotherapy drugs (mosunetuzumab or glofitamab) with newer oral drugs (iberdomide and/or golcadomide) can safely treat B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments. About 121 adults with this type of blood cancer will receive these drug combinations to see if they shrink tumors and how well patients tolerate them. The goal is to find better options for people who have run out of standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mosunetuzumab, glofitamab, iberdomide, golcadomide
What this could lead to: If successful, this could lead to more effective treatment options for people with B-cell non-Hodgkin lymphoma that has not responded to prior therapies.
What could go wrong: This is an early phase 1 trial with a small number of participants, so safety and effectiveness are not yet proven. The drug combinations may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Azienda Ospedaliero Universitaria Pisana-Ospedale Santa Chia

Pisa, Piedmont, 56126, Italy
Center Hospital

Ramat Gan, 5262199, Israel
Clinica Universidad de Navarra-Madrid

Madrid, 28027, Spain
Hadassah University Hospital - Ein Kerem

Jerusalem, 9112001, Israel
Hosp Universitario Salamanca

Salamanca, 37007, Spain
Hospital General Universitario Gregorio Maranon

Madrid, 28040, Spain
Hospital Universitari Vall d Hebron

Barcelona, 08035, Spain
Hospital Universitario La Fe

Valencia, Valencia, 46026, Spain
ICO L'Hospitalet

L'Hospitalet de Llobregat, Barcelona, 08908, Spain
IRCCS Azienda Ospedaliero Universitaria di Bologna

Bologna, Emilia-Romagna, 40138, Italy
IRCCS Istituto Romagnolo per lo studio dei tumori "Dino Amadori"

Meldola, Emilia-Romagna, 47014, Italy
Irccs Ospedale San Raffaele

Milan, Lombardy, 20132, Italy
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
NHS Greater Glasgow and Clyde

Glasgow, G12 0YN, United Kingdom
Nottingham University Hospitals City Campus

Nottingham, NG5 1PB, United Kingdom
Oxford University Hospitals NHS Trust - Churchill Hospital

Oxford, OX3 7LE, United Kingdom
Rambam Health Care Campus

Haifa, 3109600, Israel
Soroka

Beersheba, 0084101, Israel
Sourasky Medical Center

Tel Aviv, 6423900, Israel
The University of Chicago

Chicago, Illinois, 60637, United States
UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program

San Francisco, California, 94143, United States
UT MD Anderson Cancer Center

Houston, Texas, 77030, United States
University College London Hospitals

London, W1T 7HA, United Kingdom
University of Colorado

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.